Defining the molecular landscape of ependymomas
Tenley C Archer1, Scott L Pomeroy1
1Department of Neurology, Boston Children's Hospital, Harvard Medical School, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Harvard University, Cambridge, MA 02138, USA.
Cancer Cell
|May 13, 2015
Abstract:
Ependymomas have a variable prognosis. In this issue of Cancer Cell, Pajtler and colleagues identify nine subgroups of ependymoma using DNA methylation profiles. Two subgroups, predominately pediatric, are responsible for most of the mortality, with all others having nearly 100% overall survival after 5 years.
